Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction

Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy. As HFpEF patients with pulmonary hypertension display a specifically high morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgdorf, Christof, Brockmöller, Janine, Strampe, Henrieke, Januszewski, Monika, Remppis, Bjoern Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529008/
https://www.ncbi.nlm.nih.gov/pubmed/34692786
http://dx.doi.org/10.3389/fcvm.2021.734697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529008/
https://www.ncbi.nlm.nih.gov/pubmed/34692786
http://dx.doi.org/10.3389/fcvm.2021.734697

Ejemplares similares